InterPAD - DETAILS

tolazamide, 1156-19-0, Tolinase, Norglycin, Tolanase, Tolazolamide, Diabewas, Tolazamida, Tolazamidum, 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea, N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea, NSC-70762, 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea, NCI-C03327, U-17835, 4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide, CCRIS 591, U 17835, Tolazamidum [INN-Latin], Tolazamida [INN-Spanish], EINECS 214-588-3, Benzenesulfonamide, N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-, Urea, 1-(hexahydroazepin-1-yl)-3-p-tolylsulfonyl-, BRN 1323565, HSDB 3192, Urea, 1-(hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)-, 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea, N-(azepan-1-ylcarbamoyl)-4-methylbenzenesulfonamide, UNII-9LT1BRO48Q, 9LT1BRO48Q, NSC 70762, CHEBI:9613, DTXSID3021358, AI3-50826, Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methyl-, NSC70762, N-(((Hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methylbenzenesulfonamide, MLS000028534, 1-(Hexahydro-1H-azepin-1-yl)-3-(p-toluenesulfonyl)urea, DTXCID401358, N-[(azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide, 5-20-04-00062 (Beilstein Handbook Reference), Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methyl-, Tolazamide [USAN:USP:INN:BAN:JAN], NCGC00016009-10, SMR000058290, CAS-1156-19-0, Tolazamidum (INN-Latin), Tolazamida (INN-Spanish), N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methylbenzenesulfonamide, TOLAZAMIDE (MART.), TOLAZAMIDE [MART.], TOLAZAMIDE (USP-RS), TOLAZAMIDE [USP-RS], 1-(((((4-Methylphenyl)sulfonyl)amino)carbonyl)amino)azepane, 1-(4-Methylphenylsulfonyl)-3-(hexahydro-1H-azepin-1-yl)urea, TOLAZAMIDE (USP MONOGRAPH), TOLAZAMIDE [USP MONOGRAPH], N-[[(Hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methylbenzenesulfonamide, Tolazamide (USAN:USP:INN:BAN:JAN), Tolinase (TN), TOLBUTAMIDE IMPURITY C (EP IMPURITY), TOLBUTAMIDE IMPURITY C [EP IMPURITY], SR-01000003105, 1-[(Azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide, Tolazamid, 1-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]azepane, Ronase, N-{[(hexahydro-1H-azepin-1-yl)-amino]carbonyl}-4-methylbenzenesulfonamide, Prestwick_865, Spectrum_001269, TOLAZAMIDE [MI], TOLAZAMIDE [INN], TOLAZAMIDE [JAN], Opera_ID_1740, Prestwick0_000554, Prestwick1_000554, Prestwick2_000554, Prestwick3_000554, Spectrum2_001449, Spectrum3_001473, Spectrum4_000240, Spectrum5_001204, Lopac-T-2408, TOLAZAMIDE [HSDB], TOLAZAMIDE [USAN], TOLAZAMIDE [VANDF], CHEMBL817, T 2408, 3-azepan-1-yl-1-(4-methylphenyl)sulfonyl-urea, NCIOpen2_008361, TOLAZAMIDE [WHO-DD], CBiol_001918, Lopac0_001195, Oprea1_061180, SCHEMBL34417, BSPBio_000627, BSPBio_001505, BSPBio_003025, KBioGR_000225, KBioGR_000939, KBioSS_000225, KBioSS_001749, Tolazamide (JAN/USP/INN), 1-(azepan-1-yl)-3-(4-methylbenzenesulfonyl)urea, MLS001076161, DivK1c_000212, SPECTRUM1501201, SPBio_001317, SPBio_002548, BPBio1_000691, GTPL6847, NCI-CO3327, WLN: T7NTJ AMVMSWR D1, TOLAZAMIDE [ORANGE BOOK], BCBcMAP01_000061, HMS500K14, KBio1_000212, KBio2_000225, KBio2_001749, KBio2_002793, KBio2_004317, KBio2_005361, KBio2_006885, KBio3_000449, KBio3_000450, KBio3_002525, A10BB05, NINDS_000212, Bio1_000204, Bio1_000693, Bio1_001182, Bio2_000225, Bio2_000705, HMS1361L07, HMS1569P09, HMS1791L07, HMS1921P19, HMS1989L07, HMS2089L10, HMS2092L09, HMS2096P09, HMS2232L21, HMS3259O18, HMS3263P11, HMS3369L04, HMS3402L07, HMS3713P09, inverted exclamation markY96%(T), Pharmakon1600-01501201, BCP23550, HY-B0920, Tox21_110281, Tox21_201507, Tox21_300416, Tox21_501195, CCG-39178, MFCD00083504, NSC758149, AKOS015913823, Tox21_110281_1, DB00839, KS-1438, LP01195, NC00590, NSC-758149, SDCCGSBI-0051162.P004, Benzenesulfonamide, {N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-}, IDI1_000212, IDI1_033975, NCGC00016009-01, NCGC00016009-02, NCGC00016009-03, NCGC00016009-04, NCGC00016009-05, NCGC00016009-06, NCGC00016009-07, NCGC00016009-08, NCGC00016009-09, NCGC00016009-11, NCGC00016009-12, NCGC00016009-13, NCGC00016009-14, NCGC00016009-15, NCGC00016009-16, NCGC00016009-17, NCGC00016009-19, NCGC00016009-24, NCGC00023701-03, NCGC00023701-04, NCGC00023701-05, NCGC00023701-06, NCGC00023701-07, NCGC00023701-08, NCGC00023701-09, NCGC00023701-10, NCGC00254501-01, NCGC00259058-01, NCGC00261880-01, 1-(azepan-1-yl)-3-(p-tolylsulfonyl)urea, SBI-0051162.P003, AB00052247, EU-0101195, FT-0675268, NS00007143, SW196991-3, C71499, D00379, AB00052247-15, AB00052247_16, AB00052247_17, A921617, 1-(azepan-1-yl)-3-[(4-methylbenzene)sulfonyl]urea, 3-(Azepan-1-yl)-1-(4-methylphenyl)Sulfonyl-Urea, Q7814101, SR-01000003105-2, SR-01000003105-4, SR-01000003105-5, SR-01000003105-8, W-109110, BRD-K32164935-001-06-8, BRD-K32164935-001-17-5, BRD-K32164935-001-28-2, F2173-1137, Z1575267190, 1-[(([(4-Methylphenyl)sulfonyl]amino)carbonyl)amino]azepane #, Tolazamide, United States Pharmacopeia (USP) Reference Standard, Benzenesulfonamide, N-[[(hexahydro-1-azepinyl)amino]carbonyl]-4-methyl-, BENZENESULFONAMIDE, N,((HEXAHYDRO-1H-AZEPIN-1-YL)AMINO)CARBONYL)-4-METHYL-

Name	Tolazamide
PubChem CID	5503
Molecular Weight	311.40g/mol
Synonyms	tolazamide, 1156-19-0, Tolinase, Norglycin, Tolanase, Tolazolamide, Diabewas, Tolazamida, Tolazamidum, 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea, N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea, NSC-70762, 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea, NCI-C03327, U-17835, 4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide, CCRIS 591, U 17835, Tolazamidum [INN-Latin], Tolazamida [INN-Spanish], EINECS 214-588-3, Benzenesulfonamide, N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-, Urea, 1-(hexahydroazepin-1-yl)-3-p-tolylsulfonyl-, BRN 1323565, HSDB 3192, Urea, 1-(hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)-, 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea, N-(azepan-1-ylcarbamoyl)-4-methylbenzenesulfonamide, UNII-9LT1BRO48Q, 9LT1BRO48Q, NSC 70762, CHEBI:9613, DTXSID3021358, AI3-50826, Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methyl-, NSC70762, N-(((Hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methylbenzenesulfonamide, MLS000028534, 1-(Hexahydro-1H-azepin-1-yl)-3-(p-toluenesulfonyl)urea, DTXCID401358, N-[(azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide, 5-20-04-00062 (Beilstein Handbook Reference), Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methyl-, Tolazamide [USAN:USP:INN:BAN:JAN], NCGC00016009-10, SMR000058290, CAS-1156-19-0, Tolazamidum (INN-Latin), Tolazamida (INN-Spanish), N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methylbenzenesulfonamide, TOLAZAMIDE (MART.), TOLAZAMIDE [MART.], TOLAZAMIDE (USP-RS), TOLAZAMIDE [USP-RS], 1-(((((4-Methylphenyl)sulfonyl)amino)carbonyl)amino)azepane, 1-(4-Methylphenylsulfonyl)-3-(hexahydro-1H-azepin-1-yl)urea, TOLAZAMIDE (USP MONOGRAPH), TOLAZAMIDE [USP MONOGRAPH], N-[[(Hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methylbenzenesulfonamide, Tolazamide (USAN:USP:INN:BAN:JAN), Tolinase (TN), TOLBUTAMIDE IMPURITY C (EP IMPURITY), TOLBUTAMIDE IMPURITY C [EP IMPURITY], SR-01000003105, 1-[(Azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide, Tolazamid, 1-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]azepane, Ronase, N-{[(hexahydro-1H-azepin-1-yl)-amino]carbonyl}-4-methylbenzenesulfonamide, Prestwick_865, Spectrum_001269, TOLAZAMIDE [MI], TOLAZAMIDE [INN], TOLAZAMIDE [JAN], Opera_ID_1740, Prestwick0_000554, Prestwick1_000554, Prestwick2_000554, Prestwick3_000554, Spectrum2_001449, Spectrum3_001473, Spectrum4_000240, Spectrum5_001204, Lopac-T-2408, TOLAZAMIDE [HSDB], TOLAZAMIDE [USAN], TOLAZAMIDE [VANDF], CHEMBL817, T 2408, 3-azepan-1-yl-1-(4-methylphenyl)sulfonyl-urea, NCIOpen2_008361, TOLAZAMIDE [WHO-DD], CBiol_001918, Lopac0_001195, Oprea1_061180, SCHEMBL34417, BSPBio_000627, BSPBio_001505, BSPBio_003025, KBioGR_000225, KBioGR_000939, KBioSS_000225, KBioSS_001749, Tolazamide (JAN/USP/INN), 1-(azepan-1-yl)-3-(4-methylbenzenesulfonyl)urea, MLS001076161, DivK1c_000212, SPECTRUM1501201, SPBio_001317, SPBio_002548, BPBio1_000691, GTPL6847, NCI-CO3327, WLN: T7NTJ AMVMSWR D1, TOLAZAMIDE [ORANGE BOOK], BCBcMAP01_000061, HMS500K14, KBio1_000212, KBio2_000225, KBio2_001749, KBio2_002793, KBio2_004317, KBio2_005361, KBio2_006885, KBio3_000449, KBio3_000450, KBio3_002525, A10BB05, NINDS_000212, Bio1_000204, Bio1_000693, Bio1_001182, Bio2_000225, Bio2_000705, HMS1361L07, HMS1569P09, HMS1791L07, HMS1921P19, HMS1989L07, HMS2089L10, HMS2092L09, HMS2096P09, HMS2232L21, HMS3259O18, HMS3263P11, HMS3369L04, HMS3402L07, HMS3713P09, inverted exclamation markY96%(T), Pharmakon1600-01501201, BCP23550, HY-B0920, Tox21_110281, Tox21_201507, Tox21_300416, Tox21_501195, CCG-39178, MFCD00083504, NSC758149, AKOS015913823, Tox21_110281_1, DB00839, KS-1438, LP01195, NC00590, NSC-758149, SDCCGSBI-0051162.P004, Benzenesulfonamide, {N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-}, IDI1_000212, IDI1_033975, NCGC00016009-01, NCGC00016009-02, NCGC00016009-03, NCGC00016009-04, NCGC00016009-05, NCGC00016009-06, NCGC00016009-07, NCGC00016009-08, NCGC00016009-09, NCGC00016009-11, NCGC00016009-12, NCGC00016009-13, NCGC00016009-14, NCGC00016009-15, NCGC00016009-16, NCGC00016009-17, NCGC00016009-19, NCGC00016009-24, NCGC00023701-03, NCGC00023701-04, NCGC00023701-05, NCGC00023701-06, NCGC00023701-07, NCGC00023701-08, NCGC00023701-09, NCGC00023701-10, NCGC00254501-01, NCGC00259058-01, NCGC00261880-01, 1-(azepan-1-yl)-3-(p-tolylsulfonyl)urea, SBI-0051162.P003, AB00052247, EU-0101195, FT-0675268, NS00007143, SW196991-3, C71499, D00379, AB00052247-15, AB00052247_16, AB00052247_17, A921617, 1-(azepan-1-yl)-3-[(4-methylbenzene)sulfonyl]urea, 3-(Azepan-1-yl)-1-(4-methylphenyl)Sulfonyl-Urea, Q7814101, SR-01000003105-2, SR-01000003105-4, SR-01000003105-5, SR-01000003105-8, W-109110, BRD-K32164935-001-06-8, BRD-K32164935-001-17-5, BRD-K32164935-001-28-2, F2173-1137, Z1575267190, 1-[(([(4-Methylphenyl)sulfonyl]amino)carbonyl)amino]azepane #, Tolazamide, United States Pharmacopeia (USP) Reference Standard, Benzenesulfonamide, N-[[(hexahydro-1-azepinyl)amino]carbonyl]-4-methyl-, BENZENESULFONAMIDE, N,((HEXAHYDRO-1H-AZEPIN-1-YL)AMINO)CARBONYL)-4-METHYL-
Drug Type	Small molecule
Formula	C₁₄H₂₁N₃O₃S
SMILES	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2
InChI	1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)
InChIKey	OUDSBRTVNLOZBN-UHFFFAOYSA-N
CAS Number	1156-19-0
ChEMBL ID	CHEMBL817
ChEBI ID	CHEBI:9613
TTD ID	D09FJB
Drug Bank ID	DB00839
KEGG ID	D00379
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Niacinamide, Tolazamide
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.